+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Metabolic Disorder Therapeutics Market 2020-2026

  • ID: 5241083
  • Report
  • November 2020
  • Region: Global
  • Orion Market Research Private Limited
UP TO OFF
until Dec 31st 2021
1 of 3

FEATURED COMPANIES

  • AbbVie, Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • Cipla, Inc.
  • Merck KGaA
  • Orchard Therapeutics plc
  • MORE
Global Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report, By Therapy (Drug Therapy, Gene Therapy, Cellular Transplantation, Enzyme Replacement Therapy, and Others), By Disease (Obesity, Diabetes, Lysosomal Storage Disease, Hypercholesterolemia, and Others) and Forecast, 2020-2026.

The global metabolic disorder therapeutics market is estimated to witness significant growth during the forecast period. The rising prevalence of diabetes and obesity is contributing to the growth of the market. According to the International Diabetes Federation (IDF), approximately 463 million adults (20-79 years) had diabetes in 2019, which will rise to 700 million by 2045. The type-2 diabetic population is rising in most countries. In 2019, 374 million people were at increased risk of developing type 2 diabetes. Type-2 diabetes is a metabolic disorder which is characterized by pancreatic β-cell dysfunction and insulin resistance due to the unsettled high blood glucose levels (hyperglycemia).

Insulin sensitizing drugs, including thiazolidinediones and metformin, are used for the treatment of any type 2 diabetic patient. In addition, these drugs can also be used in patients suffering from metabolic syndrome. At the starting of the therapy, metformin is normally used and thereafter insulin sensitizers (PPAR-gamma stimulators) including rosiglitazone are also recommended. PPARgamma (peroxisome- proliferator-activated receptor-gamma) is considered as a crucial therapeutic target to treat diabetes which arises from its effects of hypoglycemic in diabetic patients and also plays a critical role in controlling CVD functions.

Geographically, the global metabolic disorder therapeutics market is classified into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America has the largest share in the biopharmaceutical industry, which may lead to potential share in the production and R&D of metabolic disorder treatments in the region. In addition, the region is significantly driven by the rising prevalence of metabolic disorders such as obesity and diabetes. Asia-Pacific is estimated to witness considerable growth during the forecast period owing to the rising awareness regarding health among the population and improving healthcare infrastructure in the region.

Some crucial players in the market include AbbVie Inc., Novo Nordisk A/S, Sanofi S.A., Boehringer Ingelheim GmbH, and AstraZeneca plc. Product launches, mergers and acquisitions, and partnerships and collaborations, are certain strategies adopted by the market players to expand market share and gain a competitive advantage. For instance, in March 2020, AstraZeneca plc declared that it would partner with Silence Therapeutics to discover, develop and commercialize small interfering RNA (siRNA) therapeutics for the treatment of CVD, respiratory, renal, and metabolic disorders. This multi-target partnership will use the established small interfering RNA (siRNA) platform of Silence to detect and progress liver-based targets and develop new delivery methods to target other tissues including the heart, kidney, and lung.

Research Methodology

The market study of the global metabolic disorder therapeutics market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. the team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

1. Global Metabolic Disorder Therapeutics Market Research and Analysis by Therapy
2. Global Metabolic Disorder Therapeutics Market Research and Analysis by Disease

The Report Covers:
  • Comprehensive research methodology of the global metabolic disorder therapeutics market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global metabolic disorder therapeutics market.
  • Insights about market determinants which are stimulating the global metabolic disorder therapeutics market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie, Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • Cipla, Inc.
  • Merck KGaA
  • Orchard Therapeutics plc
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules and Regulations

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. AbbVie, Inc.
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Novo Nordisk A/S
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Sanofi S.A.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Boehringer Ingelheim GmbH
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. AstraZeneca plc
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments

4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities

5. Market Segmentation
5.1. Global Metabolic Disorder Therapeutics Market by Therapy
5.1.1. Drug Therapy
5.1.2. Gene Therapy
5.1.3. Cellular Transplantation
5.1.4. Enzyme Replacement Therapy
5.1.5. Others
5.2. Global Metabolic Disorder Therapeutics Market by Disease
5.2.1. Obesity
5.2.2. Diabetes
5.2.3. Lysosomal Storage Disease
5.2.4. Hypercholesterolemia
5.2.5. Others

6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World

7. Company Profiles
7.1. AbbVie, Inc.
7.2. Actelion Pharmaceuticals, Ltd.
7.3. Agios Pharmaceuticals, Inc.
7.4. Alexion Pharmaceuticals, Inc.
7.5. Amgen, Inc.
7.6. AstraZeneca plc
7.7. Biocon, Ltd.
7.8. BioMarin Pharmaceutical, Inc.
7.9. Boehringer Ingelheim GmbH
7.10. Bristol-Myers Squibb Co.
7.11. Cipla, Inc.
7.12. CymaBay Therapeutics, Inc.
7.13. Dracen Pharmaceuticals, Inc.
7.14. Eli Lilly and Co.
7.15. Intra-Cellular Therapies, Inc.
7.16. Merck KGaA
7.17. Novo Nordisk A/S
7.18. Orchard Therapeutics plc
7.19. Pfizer, Inc.
7.20. Sanofi S.A.
7.21. Shire Pharmaceuticals Group plc
7.22. Sigilon Therapeutics, Inc.
7.23. Silence Therapeutics
Note: Product cover images may vary from those shown
3 of 3
  • AbbVie, Inc.
  • Actelion Pharmaceuticals, Ltd.
  • Agios Pharmaceuticals, Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen, Inc.
  • AstraZeneca plc
  • Biocon, Ltd.
  • BioMarin Pharmaceutical, Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co.
  • Cipla, Inc.
  • CymaBay Therapeutics, Inc.
  • Dracen Pharmaceuticals, Inc.
  • Eli Lilly and Co.
  • Intra-Cellular Therapies, Inc.
  • Merck KGaA
  • Novo Nordisk A/S
  • Orchard Therapeutics plc
  • Pfizer, Inc.
  • Sanofi S.A.
  • Shire Pharmaceuticals Group plc
  • Sigilon Therapeutics, Inc.
  • Silence Therapeutics
Note: Product cover images may vary from those shown
Adroll
adroll